CELOX LABORATORIES INC
10QSB/A, 1997-04-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CELOX LABORATORIES INC, 10QSB, 1997-04-14
Next: CNB FINANCIAL CORP /NY/, DEF 14A, 1997-04-14





                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(X)      Quarterly report under Section 13 of 15(d) of the Securities Exchange
         Act of 1934.

For the quarterly period ended FEBRUARY 28, 1997 or

()       Transition report under Section 13 or 15(d) of the Securities Exchange
         Act of 1934 for the transition period from __________ to __________.
 

Commission file number          0-19866

                            CELOX LABORATORIES, INC.
                      (Exact name of small business issuer
                          as specified in its charter)

           MINNESOTA                                         36-3384240
(State or other jurisdiction of                            (I.R.S. Employer
incorporation or organization)                           Identification Number)

1311 HELMO AVENUE, OAKDALE MN                          55128
(Address of principal executive offices)             (Zip Code)


Issuers telephone number, including area code: (612) 730-1500


Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Act of 1934 during the past 12 months (or
for such shorter periods that the issuer was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days.

                              Yes __X__   No ____

State the number of shares outstanding of each the issuer's classes of common
equity, as of the latest practicable date.

THE NUMBER OF SHARES OF COMMON STOCK, PAR VALUE $.01 PER SHARE, OUTSTANDING ON
MARCH 31, 1997 WAS 2,742,169.

Transitional small business format disclosure:

                               Yes ____   No __X__




                                Table of Contents

                            CELOX LABORATORIES, INC.

                              Report on Form 10-QSB
                            for fiscal quarter ended
                                February 28, 1997


PART I -- FINANCIAL INFORMATION                                        Page
                                                                       ----

         ITEM 1.  Financial Statements

                   Balance Sheet as of August 31, 1996
                      and February 28, 1997                              3

                   Statement of Operations -- Three months ended
                      February 28, 1997 and February 29, 1996, and
                      six months ended February 28, 1997 and
                      February 29, 1996.                                 5

                   Statement of Changes in Shareholders' Equity
                      for the year ended August 31, 1996 and the
                      six months ended February 28, 1997                 6

                   Statement of Cash Flows -- Six months ended
                      February 28, 1997 and February 29, 1996            7

                   Notes to Financial Statements                         8


         ITEM 2.  Management's Discussion and Analysis of Financial
                      Conditions and Results of Operations               10


PART II -- OTHER INFORMATION                                             14



                         PART I -- FINANCIAL INFORMATION


ITEM 1 -- FINANCIAL STATEMENTS


CELOX LABORATORIES, INC.
BALANCE SHEET
                                                 February 28,       August 31,
 ASSETS                                              1997              1996
                                                 -----------       -----------

 CURRENT ASSETS

   Cash and cash equivalents                     $   625,281       $   420,222
   Certificates of deposit                           737,213           968,663
   Trade receivables                                  42,034            91,802
   Investor settlement receivable -- current               0            57,328
   Accrued interest receivable                         5,343            19,002
   Inventories                                        48,430            74,372
   Prepaid expenses                                    6,658               814
                                                 -----------       -----------

              Total current assets                 1,464,959         1,632,203
                                                 -----------       -----------

 INVESTOR SETTLEMENT RECEIVABLE                       22,446            22,446

 EQUIPMENT AND LEASEHOLD IMPROVEMENTS

   Laboratory and production equipment               204,882           204,882
   Office furniture and equipment                     78,764            78,764
   Leasehold improvements                                  0            64,390
                                                 -----------       -----------
                                                     283,646           348,036
   Less accumulated depreciation                    (207,405)         (254,432)
                                                 -----------       -----------

                                                      76,241            93,604
                                                 -----------       -----------

              TOTAL ASSETS                       $ 1,563,646       $ 1,748,253
                                                 ===========       ===========




CELOX LABORATORIES, INC.
BALANCE SHEET

                                                February 28,       August 31,
 LIABILITIES AND SHAREHOLDERS' EQUITY                1997              1996
                                                -----------       -----------

 CURRENT LIABILITIES
    Accounts payable                            $    10,937       $    29,748
    Accrued liabilities                              51,726            33,452
                                                -----------       -----------

              Total current liabilities              62,663            63,200
                                                -----------       -----------

 DEFERRED RENT                                            0               773

 SHAREHOLDERS' EQUITY
    Common stock                                     27,422            27,422
    Additional contributed capital                5,251,756         5,251,756
                                                -----------       -----------
                                                  5,279,178         5,279,178
    Accumulated deficit                          (3,778,195)       (3,594,898)
                                                -----------       -----------

              Total Shareholders' Equity          1,500,983         1,684,280
                                                -----------       -----------

 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY     $ 1,563,646       $ 1,748,253
                                                ===========       ===========

See Notes to Financial Statements.



<TABLE>
<CAPTION>

CELOX LABORATORIES, INC.
STATEMENT OF OPERATIONS

- -------------------------------------------------------------------------------------------------------------------
                                                      Three months ended                   Six months ended
                                                 February 28,      February 29,      February 28,      February 29,
                                                     1997              1996              1997             1996
- -------------------------------------------------------------------------------------------------------------------
<S>                                             <C>               <C>               <C>               <C>        
REVENUES
  Net sales                                      $    40,032       $   134,874       $   125,737       $   249,232

  Cost of products sold                               22,227            54,697            61,894           110,221
- -------------------------------------------------------------------------------------------------------------------

GROSS MARGIN                                          17,805            80,177            63,843           139,011
- -------------------------------------------------------------------------------------------------------------------

OPERATING EXPENSES
  Research and development                            14,448            41,238            34,242            79,526
  Marketing and sales                                 44,789            51,487            75,129           123,488
  Administration                                      93,613            82,030           174,629           153,783
- -------------------------------------------------------------------------------------------------------------------

  Total operating expenses                           152,850           174,755           284,000           356,797

OPERATING LOSS                                      (135,045)          (94,578)         (220,157)         (217,786)

OTHER INCOME
  Interest and investment income                      16,245            29,898            35,819            70,921
   Other income                                            0                 0             1,041                 0
   Investment gain                                         0            12,350                 0            27,750
- -------------------------------------------------------------------------------------------------------------------

  Total other income                                  16,245            42,248            36,860            98,671

NET LOSS                                         ($  118,800)      ($   52,330)      ($  183,297)      ($  119,115)
===================================================================================================================

LOSS PER COMMON SHARE                            ($     0.04)      ($     0.02)      ($     0.07)      ($     0.04)
===================================================================================================================

WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING                          2,742,169         2,742,169         2,742,169         2,742,169
===================================================================================================================

See Notes to Financial Statements.

</TABLE>


<TABLE>
<CAPTION>

CELOX LABORATORIES, INC.
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY


- ------------------------------------------------------------------------------------------------------------------------------------
                                               Common Stock           Additional                         Unrealized
                                          ---------------------        Paid-in       Accumulated       Gain on Inv.
                                            Shares       Amount        Capital         Deficit        Avail. for Sale       Total
- ------------------------------------------------------------------------------------------------------------------------------------
<S>                                      <C>            <C>          <C>            <C>                   <C>           <C>       
BALANCE AT AUGUST 31, 1994                2,764,669      $27,647      $5,268,681     ($2,864,260)                0       $2,432,068

   Common stock repurchased                 (22,500)        (225)        (16,925)                                           (17,150)
   Unrealized gains for the period                                                                          38,798           38,798
   Net loss for the period                                                              (346,614)                          (346,614)
- ------------------------------------------------------------------------------------------------------------------------------------

BALANCE AT AUGUST 31, 1995                2,742,169      $27,422      $5,251,756     ($3,210,874)          $38,798       $2,107,102

  Net changes in unrealized gains for
    the year                                                                                               (38,798)         (38,798)
  Net loss for the period                                                               (384,024)                          (384,024)
- ------------------------------------------------------------------------------------------------------------------------------------

BALANCE AT AUGUST 31, 1996                2,742,169      $27,422      $5,251,756     ($3,594,898)               $0       $1,684,280

  Net loss for the period                                                               (183,297)                          (183,297)
- ------------------------------------------------------------------------------------------------------------------------------------

BALANCE AT FEBRUARY 28, 1997              2,742,169      $27,422      $5,251,756     ($3,778,195)               $0       $1,500,983

See Notes to Financial Statements.

</TABLE>


<TABLE>
<CAPTION>

CELOX LABORATORIES, INC.
STATEMENT OF CASH FLOWS


- -----------------------------------------------------------------------------------------------------------
                                                                                      Six months ended
                                                                                 February 28,   February 29,
                                                                                     1997           1996
- -----------------------------------------------------------------------------------------------------------
<S>                                                                              <C>             <C>       
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss for the period                                                         ($183,297)      ($119,115)
  Adjustments to reconcile net loss to
   net cash used in operating activities:
       Depreciation and amortization                                                 17,363          23,735
       Deferred rent expense                                                           (773)         (2,313)
       Changes in assets and liabilities:
           (Increase) decrease in:
               Accounts receivable                                                   49,768         (82,955)
               Accrued interest receivable                                           13,658          12,764
               Inventories                                                           25,942          (4,719)
               Prepaid expenses                                                      (5,845)           (834)
               Officer note receivable                                                    0           4,000
           Increase (decrease) in:
               Accounts payable                                                     (18,811)          8,150
               Accrued liabilities                                                   18,275          (1,492)
- -----------------------------------------------------------------------------------------------------------

               Net cash used in operating activities                                (83,720)       (162,779)
- -----------------------------------------------------------------------------------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Maturity (Purchase) of bank certificates of deposit                               231,450        (767,784)
  Proceeds from sale of short-term investments held for sale                              0         692,042
  Proceeds from investor settlement receivables                                      57,329               0
  Purchase of equipment                                                                   0         (12,841)
- -----------------------------------------------------------------------------------------------------------

               Net cash from (used for) investing activities                        288,779         (88,583)
- -----------------------------------------------------------------------------------------------------------

               Net increase (decrease) in cash
                 and cash equivalents                                               205,059        (251,362)

CASH AND CASH EQUIVALENTS:
  Beginning of period                                                               420,222         919,404
- -----------------------------------------------------------------------------------------------------------

  End of period                                                                   $ 625,281       $ 668,042
===========================================================================================================

See Notes to Financial Statements.

</TABLE>



CELOX LABORATORIES, INC,
NOTES TO FINANCIAL STATEMENTS -- FEBRUARY 28, 1997


NOTE A -- BASIS OF PRESENTATION

     The accompanying financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information and
with the instructions to Form 10-QSB and Item 310 of Regulation S-B.
Accordingly, they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial statements.
In the opinion of management, all adjustments (consisting only of normal
recurring adjustments) considered necessary for a fair presentation have been
included.

     The organization and business of the Company, accounting policies followed
by the Company and other information are contained in the notes to the Company's
financial statements filed as part of the Company's August 31, 1996 Form 10-KSB.
This quarterly report should be read in connection with such annual report.


NOTE B -- CASH AND CASH EQUIVALENTS

     For purposes of reporting the statements of cash flows, the Company
considers all highly liquid debt instruments purchased with a maturity of three
months or less to be cash equivalents.


NOTE C -- SHORT-TERM INVESTMENTS

     The Company had invested excess cash in the Piper Jaffray Institutional
Government Income Portfolio Fund (Piper Fund). During the quarter ended February
29, 1996, the Company sold all remaining shares in this Fund.

     As an alternative to the Piper Fund, the Company has utilized Bank
Certificates of Deposit. As of February 28, 1997 the Company had investments of
$737,213 in Certificates of Deposit. Certificates of deposit are made only with
the highest rated banks and less than $100,000 is deposited at any one bank. The
Company also utilizes a money market fund, which is restricted by its charter to
Tier 1 instruments, for a portion of its investments.


NOTE D -- REPURCHASE OF COMMON STOCK

     Effective July 30, 1993, the Board of Directors authorized the repurchase
of up to 300,000 shares of the Company's common stock in open market
transactions at prices not to exceed $1.75 per share. At February 28, 1997 the
Company had repurchased 136,700 shares at prices ranging from $0.85 to $1.58 per
share.


NOTE E -- FACILITY LEASE AGREEMENT

     The Company's new facility is located at 1311 Helmo Avenue in Oakdale,
Minnesota. A new Lease Agreement was executed on December 6, 1996 and calls for
the lease of 9,500 square feet of office, laboratory and warehouse space. The
term of the lease is seven (7) years with an option to renew for extended
periods. Base rent for each of the seven (7) years is $73,725 plus charges for
common area maintenance and other tenant expenses. The initial lease payment
commenced April 1, 1997.


NOTE F -- LOSS PER COMMON SHARE

     Loss per share is computed based upon the weighted average number of common
shares outstanding during the period. The Company has determined that under the
modified treasury stock method, there would be no change in earnings per share
due to outstanding common stock equivalents. Fully diluted and primary loss per
share are the same amounts for each of the periods presented.


NOTE G -- RECLASSIFICATION

     Certain 1996 amounts have been reclassified to conform with the 1997
presentation. These reclassifications had no effect on net income (loss) as
previously reported.



ITEM 2 -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
          RESULTS OF OPERATIONS


INTRODUCTION

     Celox Laboratories, Inc. ("Celox" or the "Company") is a biotechnology
company formed in 1985 that researches, develops, manufactures and markets cell
biology products used in the propagation of cells derived from mammals,
including humans, and other species. These specialized cell growth products are
used primarily in academic, pharmaceutical, diagnostic and other commercial
laboratories to improve the growth condition, productivity and quality of
cell-derived medical and other biological products such as vaccines, monoclonal
antibodies, interferons and human growth factor. The Company focuses primarily
on solving the fundamental problems associated in culturing cells with the use
of serum, which is derived from the whole blood of animals and humans. The
Company's research activities have resulted in proprietary technology which has
been used to commercialize its non-serum growth media, cell freezing solutions
and other cell biology products.

     Celox currently manufactures and markets over 30 products. Celox's
proprietary products consist of four serum replacement products, TCM,
TM-235(TM), TCH(TM), and VaxMax(TM) and a cell freezing medium, Cellvation(TM).
VaxMax(TM) was developed specifically for use in the production of veterinary
vaccines.

     Celox also manufactures ten basal media formulations, a series of buffered
salt solutions, other cell biology reagents and a variety of custom
formulations.

     An additional proposed product, ViaStem(TM), continues to undergo further
analysis in pre-clinical testing. This product was developed to improve the
preservation of critical cells (e.g. stem cells) which are required for bone
marrow transplantation. Other potential applications for ViaStem(TM) include the
preservation of umbilical cord blood and platelets. Currently, Memorial Blood
Centers of Minnesota and the University of Cincinnati's Hoxworth Blood Center
will be providing additional pre-clinical data on ViaStem(TM).

     During the quarter ended November 30, 1996, the Company received notice
from the United States Patent and Trademark Office (USPTO) that a patent for
ViaStem(TM) would be issued in early December, 1996. The actual patent was
received by the Company in the first week of December. The Company has also
filed the documents needed for an International Patent Application as required
by the Patent Cooperation Treaty.

     During February, 1996 the Company entered into an agreement with the
Department of the Army, Walter Reed Army Institute of Research (WRAIR) that
provides for a Cooperative Research and Development Agreement for Material
Transfer which encompasses the Company's ViaStem(TM) product.

     The Company has received its first Drug Master File classification from the
Food and Drug Administration (FDA) for TCM. This classification will expedite
the FDA approval process for customers who want to use the Company's TCM product
in the manufacture of drugs or drug substances for human use. The Company is in
the process of gaining similar status for its other proprietary products.

     In April, 1994, the Company entered into an agreement with American Type
Culture Collection (ATCC), Rockville, MD, the world's largest public archive of
living biological cultures and genetic materials. ATCC serves the international
scientific community by acquiring, preserving and distributing strains of the
most diverse collection of organisms and derivative biological materials in the
world. Under the agreement, ATCC will distribute cell lines adapted to the
Company's non-serum products as well as other associated products worldwide.
Orders for growth media under this agreement have continued during the current
fiscal year.

     During July of 1995, the Company completed a non-exclusive world-wide
distribution agreement with ICN Pharmaceuticals, Inc., Costa Mesa, CA. Under the
agreement, ICN is marketing Celox's TCM, TCH(TM), TM-235(TM) serum replacement
products as well as Cellvation(TM). Initial orders under this agreement were
shipped in the last quarter of Fiscal 1995. Additional orders have been received
during the first six months of this fiscal year.

     The Company has also entered into an agreement with ICN to provide the rest
of the Company's products (except for ViaStem(TM)) to ICN for worldwide
distribution. The first shipment of these additional products will occur in the
third quarter of this fiscal year.

     ICN manufactures and markets a broad range of prescription and
over-the-counter pharmaceuticals, medical diagnostic products and biotechnology
research products in North and Latin America, Eastern and Western Europe and the
Pacific Rim countries.

     Beginning in fiscal 1997, the Company is providing its proprietary products
to Sigma Chemical Company under a private label distribution agreement. The
first shipment under this agreement occurred during the quarter ended November
30, 1996.


RESULTS OF OPERATIONS

     The Company had recorded an Investor Settlement Receivable in the amount of
$133,000 on the Balance Sheet in order to reflect the expected settlement
proceeds from a class action lawsuit which was brought on behalf of investors in
the Piper Fund. In December, 1995, the District Court Judge approved the Class
Action Settlement. Payments from the Piper Fund have been received in accordance
with the schedule agreed upon in the settlement. As of February 28, 1997 the
Investor Settlement Receivable is $22,446.

     A separate Class Action lawsuit against the Fund's auditors, KPMG Peat
Marwick, has been certified by the Court.

     During the quarter ended February 28, 1997, the Company had net sales of
$40,032 which was a decrease of $94,842 or 70% from $134,874 reported in the
same quarter for the prior year. For the six months ended February 28, 1997 net
sales totaled $125,737, versus $249,232 for the six months ended February 29,
1996. This represents a decrease of 50% from the previous period. The decrease
between years for the quarter results primarily from the timing of orders
received from a large manufacturer. In addition, the Company was forced to lease
temporary office space while it awaited completion of its new facility, which
encountered lengthy construction delays and as a result products for sale could
not be manufactured during the quarter. Product sales for the quarter ended
February 28, 1997 were limited to inventory on hand. Both of these factors also
contributed to the decline between years for the comparable six month period.

     The Company had a net loss of $118,800 for the quarter ended February 28,
1997 compared to a net loss of $52,330 for the same period in the previous year.
For the six month period, a net loss of $183,297 was incurred in fiscal 1997 as
compared to a net loss of $119,115 in fiscal 1996. On a per share basis, the
loss for the current quarter equaled 4 cents versus a 2 cent loss in the
comparable period in fiscal 1996. For the six months ended February 28, 1997 the
net loss per share was 7 cents compared to a net loss of 4 cents per share in
the prior year.

       The cost of products sold was 56% of net sales for the three months ended
February 28, 1997, as compared to 41% of net sales for the three months ended
February 29, 1996. For the six month period, cost of products sold was
49%compared to 44% during the same period in the previous fiscal year. The
increase in the cost of sales for each of the respective reporting periods is
due primarily to lower sales volume to cover fixed manufacturing costs. The mix
of proprietary products versus standard formulations will also affect
comparisons between periods. Labor, raw materials and other production costs
have been consistently controlled in light of the decline in sales for the
periods.

     An operating loss of $135,045 was generated for the quarter ended February
28, 1997 compared to an operating loss of $94,578 for the same period in the
previous year. For the six months ended February 28, 1997 the Company had an
operating loss of $220,157 versus a loss of $217,786 for the six months ended
February 29, 1996. The increase between years for both reporting periods is due
to a decline in sales. Operating expenses have decreased offsettting the decline
in sales.

     The Company received interest and investment income of $16,245 during the
quarter ended February 28, 1997 as compared to $29,898 in the prior year.
Interest and investment income for the six month period was $35,819 in fiscal
1997 compared to $70,921 for the same period in 1996. Investment income is
derived primarily from the investment of the proceeds of the Company's March
1992 initial public offering. The decrease in investment income during the
quarter as compared to the previous year results from reduced investment
balances as the Company used capital in its operations as well as lower
effective interest rates resulting from a transfer of amounts from the Piper
Fund into bank certificates of deposit. Additionally, in the quarter ended
November 30, 1995, the Company received special one-time dividend paid out from
the Piper Fund which contributes to the variance for the six month comparison.

     For both the quarter and the six months ended February 28, 1997 the Company
had no investment gains compared to investment gains of $12,350 and $27,750 for
the respective quarter and six month periods during the previous fiscal year. In
the prior year, gains were realized when shares of the Piper Jaffray fund were
sold.

     As was disclosed in previous sections of this Form 10-QSB, Piper Jaffray
and the Class Action Plantiffs have agreed to settle a lawsuit which was brought
against the Piper Fund by investors. A lawsuit filed against the Fund's
auditors, KPMG Peat Marwick, is still being pursued by investors other than the
Company. The Company has not filed a lawsuit nor has it declined if it will join
in any future class actions, but has not eliminated these options as a
possibility in the future.

     Operating expenses decreased $21,905 (13%) to $152,850 from $174,755 for
the quarter ended February 28, 1997 and decreased by $72,797 (20%) to $284,000
from $356,797 for the six months ended February 28, 1997 compared to the
comparable periods in the prior fiscal year. The decrease for both the three and
six month periods as compared to the prior year is due to the timing and amount
of research and development expenditure as well as reduced marketing and sales
expenses offset by higher administrative expenditures.

     Research and development costs decreased by $26,790 (65%) to $14,448 from
$41,238 in the current quarter as compared to the previous fiscal year. For the
comparative six month periods, research and development expenses decreased by
$45,284 (57%) to $34,242 from $79,526. The decrease for both of the reporting
periods results from the timing of expenditures in the areas of salaries and
wages and patent expenses incurred in connection with ViaStem(TM) product. The
Company expects the costs of research and development to fluctuate based on the
status of pre-clinical trials for ViaStem(TM) .

     Marketing expenses decreased by $6,698 (13%) to $44,789 from $51,487 for
the quarter ended February 28, 1997 and by $48,359 (39%) to $75,129 from
$123,488 for the six months then ending as compared to the comparable periods in
fiscal 1996. The decreases are attributed to the amount and timing of
advertising, promotional materials and trade show expenses between years. The
Company has instituted a focused advertising and marketing strategy and
therefore expects that marketing and sales expenses will increase during
subsequent quarters as programs and advertising materials are developed.

     Administrative expenses increased by $11,583 (14%) for the quarter ended
February 28, 1997 compared to the previous fiscal year to $93,613 from $82,030.
For the six months ended February 28, 1997 administrative expenses increased by
$20,846 (14%) to $174,629 from $153,783 in the prior year. The increase between
years is primarily due to moving expenses incurred as part of the Company's move
to the new facility as well as increased legal expenditures.


LIQUIDITY AND CAPITAL RESOURCES

     Capital resources on hand at February 28, 1997 include cash and short-term
investments of $1,362,494 and net working capital of $1,402,296. This represents
a decrease of $26,391 (2%) in cash and short-term investments and a decrease of
$166,707 (11%) in net working capital as compared to August 31, 1996.

     The lease for the Company's previous facility terminated in October, 1996.
A new facility has been completed in Oakdale, Minnesota, a suburb of St. Paul.
The Company has leased approximately 9,500 square feet of office, laboratory and
warehouse space in this facility during March 1997. In the interim, the Company
had leased office and warehouse space on a month-to-month basis.

     The Company anticipates spending approximately $175,000 in fiscal 1997 on
capital expenditures. Through February 28, 1997 the Company has not made any
capital expenditures. The majority of the planned expenditures will be used to
fund additional sales, research and development, manufacturing growth and
specialized tenant improvements. It is anticipated that the tenant improvements
will be financed through a local financial institution.

     The Company believes that its capital resources on hand at February 28.
1997, together with revenues from product sales, will be sufficient to meet its
cash requirements for the near future.



                          PART II -- OTHER INFORMATION


ITEM I. -- LEGAL PROCEEDINGS

     The Company is a member of the class in the KPMG Peat Marwick action as it
relates to their audit of the Piper Jaffray Institutional Government Income
Portfolio Fund, on whose behalf litigation has been commenced in federal
district court in Minneapolis. The Company has not directly participated in the
litigation and the Company does not believe any material developments in the
status of the litigation occurred during the quarter which is the subject of
this report.

     The Company is a defendant in a wrongful termination lawsuit brought by a
former employee who was in the probationary period at the time of the
termination. The Company believes that the lawsuit is without merit. However, it
has participated in an arbitration hearing in order to bring closure to this
lawsuit. As of February 28, 1997, a final settlement document still has not been
executed.


ITEM 2. -- CHANGES IN SECURITIES

     None


ITEM 3. -- DEFAULTS UPON SENIOR SECURITIES

     None


ITEM 4. -- SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     None


ITEM 5. -- OTHER INFORMATION

     None


ITEM 6. -- (A) EXHIBITS

     10.6 Lease Agreement with Oakdale Properties LLC located at 1311 Helmo
Avenue, Oakdale, Minnesota dated December 6, 1996.

     27 Financial Data Schedule.

           (B) REPORTS ON FORM 8-K

               None



                                   SIGNATURES

     In accordance with the requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                         CELOX LABORATORIES, INC.


Dated: April 11, 1997                    By: /s/ Milo R. Polovina
                                             ------------------------------
                                             Milo R.  Polovina, President &
                                             Principal Financial Officer




                             OAKDALE PROPERTIES LLC
                           COMMERCIAL LEASE AGREEMENT

THIS LEASE AGREEMENT made and entered into this 6th day of December, 1996 by and
between OAKDALE PROPERTIES LLC, Lessor, and Celox Laboratories. Inc., Tenant.

                                  WITNESSETH:

DEMISED
PREMISES:

The Lessor, in consideration of the rents and covenants herein contained to be
paid, kept and performed by the Tenant, does hereby demise, lease and let unto
the Tenant, and the Tenant does hereby hire and take from the Lessor the
following described premises, lying and being in the County of Washington, State
of Minnesota, to-wit: 1309 and 1311 Helmo Avenue No., Oakdale MN 55128
containing 9,513 square feet of floor space in a 15,528 square foot
office/warehouse building located in the City of Oakdale, Minnesota; said space
hereinafter called the "leased premises" being measured from the outside of
exterior walls to the center of partition walls or center of hallway, and to be
completed and finished in accordance with the attached specifications marked
Exhibit "A" and made a part hereof and in accordance with the attached floor
plan marked Exhibit "C" and made a part hereof.

USE:

The Lessor is leasing to the Tenant the above described Leased Premises and the
Tenant agrees that it will use the above-described Premises for the purpose of
Office Warehouse Research Development and Manufacturing and related activities
thereto and for no other purpose whatsoever.

TERM:

Tenant takes from the Lessor the Leased Premises, upon the terms and conditions
herein contained, to have and to hold the same for the term of 7 years
commencing on the 1st day of February, 1997 and terminating on the 31st day of
January, 2004, or, if the Leased Premises are not available for occupancy, the
term shall commence on the date when the Leased Premises are substantially
completed and are available to the Tenant for occupancy or on the date when the
Tenant accepts occupancy of the Leased Premises, whichever date first occurs. In
the event the expiration date shall be on a date other than the last day of a
calendar month, the term of the Lease shall be extended to and shall expire on
the last day of such calendar month, with rent to be apportioned for such
extended term on a prorated daily basis.

BASE RENT:

Tenant agrees to pay Lessor for the Leased Premises a base rental at the rate
of SEVENTY THREE THOUSAND SEVEN Hundred TWENTY FIVE and 75/100 ($73,725.75)
Dollars per year, payable in equal monthly installments of SIX THOUSAND ONE
HUNDRED FORTY THREE AND 81/100 ($6,143.81) Dollars in advance on the first day
of each calendar month (A prorated monthly installment shall be paid at the then
current rate for any fraction of a month if the term shall begin on any day
except the first day of a month ) In addition, Tenant agrees to pay Lessor
monthly installments required under the terms of RENTAL ADJUSTMENT, clause 2,
hereinafter provided. All payments shall be made at the office of the Lessor
located at 1260 Helmo Avenue North, Oakdale, Minnesota 55128 or at such other
place as may from time to be designated by the Lessor in lawful money of the
United States payable to OAKDALE PROPERTIES LLC without any offset or deductions
whatsoever. Tenant agrees to pay Lessor a late fee of 1.5% per month on any
monthly installments not paid by the 5th of the month.

RENTAL
ESCALATION:

On the 7th anniversary of the lease term, the base rent payable by the Tenant
shall be increased to an amount equal to the greater of 115% of the base rent,
or an amount determined by multiplying the base rent by a fraction, the
denominator of which shall be the most recent Consumer Price Index figure, 
hereinafter defined, published prior to the lease term, and the numerator of
which shall be the most recent Consumer Price Index figure published prior to
the date of the adjustment. As used herein, the term "Consumer Price Index"
shall mean the United States Department of Labor's Bureau of Labor Statistics,
CPI-U, All Items, Minneapolis-St. Paul, MN-WI, (1982 equals 100), or the
successor of that index Should Lessor lack sufficient data to make the proper
determination on the date of any adjustment, the Tenant shall continue to pay
the monthly base rent payable immediately prior to the adjustment date. As soon
as Lessor obtains the necessary data, he shall determine the base rent payable
from and after such adjustment date and notify the Tenant of the adjustment in
writing. Should the monthly base rent for the period following the adjustment
date exceed the amount previously paid by the Tenant for that period, the tenant
shall forthwith pay the difference to Lessor.

RENTAL
ADJUSTMENT:

In Addition to the base rent referred to above, the Tenant shall pay its
proportionate share of any real estate taxes, including installments of special
assessments, and the cost of operations and maintenance of 1309 and 1311 Helmo
Avenue No., Oakdale, MN 55128 and the appurtenant land thereto.

1.   It is agreed that the Tenant's proportionate share of any real estate taxes
     and the cost of operations and maintenance shall be determined on a ratio
     of the Tenant's leasable square footage to the total number of leasable
     square feet within the buildings. For the purpose of this Lease the
     Tenant's leasable square footage is 9,513 and the total leasable square
     footage within the Buildings is 29,294 square feet. The Tenant's
     proportionate share shall therefore be 32.47%. It is mutually agreed that
     operations and maintenance costs shall include, but not be limited to, the
     following annual expenses of the Lessor:

*    Insurance Premiums;

*    Water and sewer charges not paid or reimbursed by Tenant;

*    Electrical power charges not paid or reimbursed by Tenant;

*    Lawn care;

*    Snow removal;

*    Maintenance Assessments against the property of which the demised premises
     form a part;

     Wages, materials and services necessary for the operation and maintenance
     of the property of which the demised premises form a part.

     All of the above are accrued and based upon a calendar year operation
     Further, any expenditure for equipment or improvements which result in the
     reduction of operating expenses may be charges as an operating expense and
     amortized over a reasonable period of time. Operating expenses shall not
     include: depreciation the Building(s), interest expense, advertising or
     estate broker's commissions.

     2. The Tenant's proportionate share of taxes and operating expenses of the
     Building(s) shall be estimated in advance by Lessor, and such estimate
     shall be paid in advance by Tenant promptly upon receipt of monthly bills
     therefor from Lessor without any deduction or setoff whatever. For the
     initial calendar year of the lease term, the Tenant's estimated share of
     taxes and operating expenses shall be $XXX.XX per month. Such amounts shall
     be held by Lessor for the payment of taxes and operating expenses. The
     Lessor will furnish the Tenant with a statement of the Tenant's
     proportionate share of taxes and operating expenses after the end of each
     calendar year. The Tenant shall pay the Lessor, within 15 days after
     receipt of such statement, the amount, if any, equal to the difference
     between the Tenant's proportionate share of the actual taxes and costs of
     operations and maintenance for such calendar year and the estimated amount
     paid by Tenant during such calendar year.


COVENANTS OF TENANT:  THE TENANT HEREBY AGREES AS FOLLOWS;

Acceptance of
Premises

1.   Taking possession of the Leased Premises by Tenant Shall be conclusive
     evidence the Leased Premises were on that date, in good, clean and
     tenantable condition and as represented by Lessor.

Rules and 
Regulations

2.   To observe and strictly comply with the attached rules and regulations
     relating to the Leased Premises and the Building of which said premises
     are a part. The Lessor shall have the right, at any time or times
     hereafter, to adopt other or additional reasonable rules and regulations,
     and to rescind or reasonably amend all or any of the attached rules and
     regulations. The Lessor shall give written notice to the Tenant of the
     adoption of any additional rules and regulations or of amendments to any of
     the rules and regulations attached.

Assignment and
Subletting

3.   Not to assign this Lease or sublet any portion of the Leased Premises
     without first securing the written consent of the Lessor which consent will
     not be unreasonably withheld, and which consent, if given, shall not
     release the Tenant from its obligations hereunder. If any such assignment
     or subletting is at a higher rental than is provided for in this Lease, any
     such excess shall payable to the Lessor.

Signs

4.   Tenant shall permit no signs to be placed on the Leased Premises except as
     that provided by Lessor to be located in the center window panel adjacent
     to Tenant's entry door. Tenant identification will be to all specifications
     of Lessor. Upon approval of Lessor, Tenants shall be allowed to put up a
     temporary sign(s) or use temporary mobile signs to promote its special
     warehouse sales, provided sign(s) do not unreasonably affect the business
     of other Tenants and are in accordance with the City of Oakdale ordinances.

Rubbish and
Debris

5.   Tenant is responsible for removal of all rubbish, debris and waste material
     from leased space.

Waste

6.   Tenant shall conserve heat, air conditioning, water and electricity and
     shall use due care in the use of the Leased Premises and of the public
     areas in the Building, and without qualifying the foregoing, shall not
     neglect or misuse water, fixtures, electric lights, heating and air
     conditioning apparatus.

Lessor's Right to
Enter Premises

7.   Lessor, or its authorized agents or attorney, may with twenty-four (24)
     hours prior notice enter the Leased Premises to inspect, make repairs and
     improvements in the Leased Premises as Lessor may deem proper and there
     shall be no diminution of rent or liability on the part of the Lessor by
     reason of inconvenience, annoyance or injury to business. The Lessor shall
     have the right during the last ninety (90) days of the term of this Lease
     to enter the Leased Premises with forty-eight (48) hours prior notice for
     the purpose of showing the Leased Premises to prospective tenants.

Indemnity

8.   Lessor shall not be liable to Tenant, or those claiming through or under
     Tenant, for injury, death or property damage occurring in, or about the
     Building and appurtenances thereto, and Tenant shall indemnify Lessor and
     hold it harmless from any claim or damage arising out of any injury, death
     or property damage occurring in, on or about the Leased Premises to Tenant
     or an employee, customer or invitee of Tenant.

Insurance

9.   Tenant will procure at his own expense and keep in force during the term of
     this lease and any extension and during the time he is doing construction
     and improvement work before occupancy, a policy or policies of
     comprehensive general liability insurance, including contractual liability
     for this agreement, in an insurance company approved by the Lessor and
     qualified to do business in Minnesota with minimum limits of not less than
     $500,000 for injury to one person and not less than $1,000,000 for injury
     to more than one person in any one accident and not less than $100,000 for
     property damage, or, in the alternative, Tenant shall carry a comprehensive
     general liability policy with a combined single limit of $1,000,000
     covering bodily injury to one or more persons and property damage. These
     policies will name the Lessor as an additional insured and will cover the
     entire Leased Premises. These policies shall be endorsed prohibiting
     cancellation or termination unless the Lessor is given at least thirty (30)
     days' written notice of the intent to cancel or terminate such policies.
     The Tenant will deposit with the Lessor a certificate of insurance together
     with the receipted bill for the premium paid.

Maintenance by Tenant

     10. The Tenant shall be wholly responsible for the interior maintenance of
     the demised premises, and will keep them in as good condition as when
     turned over to it, reasonable wear and tear and damage by fire and the
     elements excepted; and will keep them in an orderly, clean and sanitary
     condition as required by the laws and ordinances applicable thereto; will
     neither do nor permit to be done on said premises anything in violation
     of the laws or ordinances applicable thereto; will neither commit nor
     suffer waste in said premises.

     Tenant agrees to replace with glass of the same kind and quality now or
     hereafter in the demised premises, including, but not limited to, the glass
     in the windows thereof that may be damaged or broken from and after the
     time Tenant occupies the demised premises and during the leasehold term,
     except if such damage or breakage is occasioned by fire, windstorm or other
     casualty covered by the insurance secured by Lessor or due to structural
     defects in or the settling of the building whereof the demised premises are
     a part.

     It is agreed that the maintenance and repair obligations of the Tenant
     hereunder shall extend to all interior parts or portions of the demised
     premises, and shall include heating, plumbing, electrical and mechanical
     fixtures equipment, connections and appurtenances except as such items may
     be covered by manufacturer warranties.

     Tenant shall at all times keep the demised premises in a neat and clean
     condition and free from garbage, ashes, offal and accumulation of rubbish
     or filth, and all garbage, offal and rubbish shall be removed promptly by
     Tenant at its own expense.

     Tenant shall keep the sidewalks in front of, in the rear of and around the
     demised premises swept and in a neat and orderly condition free from ice
     and snow and other obstructions.

     Tenant shall not without consent of Lessor exhibit or display any
     merchandise for sale on the sidewalks or anywhere outside of the demised
     premises, and shall not place on the sidewalks any signs or advertising
     materials.

     Tenant shall keep the means of ingress and egress to the demised premises
     free from obstructions, except as necessary for brief periods for
     deliveries. Tenant agrees to comply with all laws and regulations in the
     conduct of business on the demised premises.

     Should Tenant fail to make repairs called for in this paragraph, Lessor may
     make said repairs and bill Tenant as additional rent due on the next
     regular rent installment.

Maintenance by Lessor

11.  The Lessor shall keep and maintain in good condition and tenantable
     condition the roof, exterior walls, structural parts of the premises and
     structural floor. For a period of one year, Lessor shall also repair any
     defects in the interior of the demised premises, including heating,
     plumbing, electrical and mechanical fixtures, equipment, connections and
     appurtenances which arise due to lack of good workmanship or defective
     materials used in constructing the premises. Tenant shall have the benefits
     of any extended warranties for any of the items listed in the paragraph if
     same are available to Lessor through any installer or manufacturer thereof.

     The Lessor shall be responsible for all outside maintenance of the demised
     premises, including lighting grounds and parking areas. Parking areas shall
     be available to the Tenant, its employees and business invitees as well as
     to other tenants and customers of the center. The use of such parking
     facilities shall at all times be subject to such reasonable rules and
     regulations as the Lessor may promulgate uniformly for all the Lessor's
     tenants in the office center. 
     
     The Tenant will neither use nor permit theuse by its employees of the
     outside parking areas for the overnight storage of automobiles or other
     vehicles.

     All services which are the responsibility of the Lessor shall be
     provided shall be reasonably necessary to the comfortable use and occupancy
     of premises during normal trade.

Waiver of
Subrogation

12.  Notwithstanding anything in this Lease to the contrary, if the Building(s)
     is damaged or destroyed by fire or an extended coverage risk, the Tenant,
     its agents, employees, representatives and invitees are hereby released
     from any liability by reason thereof to the extent of insurance proceeds
     realized by the Lessor as a result of such damage or destruction.

Light and Air

13.  Tenant has no right to light or air space over any premises adjoining the
     Building(s).

Alterations

14.  Tenant will not make any alterations of or additions to the Leased Premises
     without the written approval of Lessor and all alterations, additions or
     improvements which may be made by either of the parties hereto upon the
     Leased Premises, except movable office furnishings, shall be the property
     of Lessor and shall remain upon and be surrendered with the leased Premises
     as part thereof, at the termination of this Lease or any extension thereof.
     Tenant will not permit any mechanics', laborers', or materialmen's liens to
     stand against the Leased Premises or the Building(s)for any labor or
     material furnished to, or for the account of Tenant, or claimed to have
     been so furnished in connection with any work performed or claimed to have
     been performed in, on or about the Leased Premises.

Subordination

15.  The Lease Agreement and all rights of Tenant thereunder including, but not
     limited to, any purchase options or other rights to acquire title to the
     Leased Premises or any part thereof, and Tenant's interest in the Leased
     Premises shall be and hereby are declared subject and subordinate to all
     ground or underlying leases, mortgages and restrictions which may now or
     hereafter affect the building and to all renewals and extensions thereof.

Nondisturbance

16.  So long as Tenant is not in default (beyond any period specified in the
     Lease Agreement for Tenant to cure such default) in the payment of rent or
     additional rent or in the performance of any of the terms, covenants or
     conditions of the Lease Agreement on Tenant's part to be performed,
     Tenant's possession of the Leased Premises and Tenant's rights and
     privileges under the Lease Agreement or any extensions or renewals thereof,
     as provided for in the Lease Agreement, shall not be diminished or
     interfered with and Tenant's occupancy of the Leased Premises shall not be
     disturbed for any reason whatsoever during the term of the Lease or any
     such extensions or renewals thereof.

Actions Against Tenant

     17. So long as Tenant is not in default (beyond any period specified in the
     Lease Agreement for Tenant to cure such default) in the payment of rent or
     in the performance of any of the terms, covenants or conditions of the
     Lease on Tenant's part to be performed, Tenant will not be joined as a
     party defendant in any action or proceeding foreclosing any mortgage
     covering the Leased Premises unless such joinder is necessary to foreclose
     such mortgage and then only for such purpose and not for the purpose
     terminating the Lease Agreement.

Attornment

18.  If the interests of the Lessor shall be transferred by reason of
     foreclosure or other proceedings in lieu of or pursuant to a foreclosure,
     or by any other manner, and such transferee succeeds to the interest of the
     Lessor under Lease Agreement, Tenant shall be bound to such transferee
     under all of the terms, covenants and conditions of the Lease Agreement for
     the balance of the term thereof and any extensions or renewals as provided
     in the Lease Agreement, with the same force and effect as if such
     transferee were the landlord under the Lease Agreement, and Tenant does
     hereby attorn to such transferee as its landlord, such attornment to be
     effective and self-operative immediately upon receipt of written notice by
     Tenant (such transferee hereby agreeing to provide a copy of such notice to
     the Lessor) to the effect that such transferee has succeeded to said
     interest of the Lessor without the execution of any further instruments
     evidencing such attornment and Tenant shall thereafter pay all rent to such
     transferee. The respective rights and obligations of Tenant and such
     transferee upon such attornment to the extent of the then remaining balance
     of the term of the Lease Agreement and any extensions and renewals shall be
     and are the same as now set forth herein.

Liability of Transferee

19.  If such transferee shall succeed to the interest of the lessor under the
     Lease Agreement, such transferee shall not (i) be liable for any act or
     omission of the Lessor; (ii) be subject to any offsets or defenses against
     the Lessor if such transferee cures the Lessor's defaults; (iii) be bound
     by payment of any rent or additional rent paid for more than one (1) month
     in advance (iv) be bound by any amendment or modification of the Lease
     Agreement made without its consent; (v) have any obligation with respect to
     any security deposit made to the Lessor, unless physically deposited with
     such transferee or (vi) be required under the terms of the Lease Agreement
     to complete the building contemplated by the Lease Agreement if such
     transferee succeeds to the interest of the Lessor in the Leased Premises
     prior to final completion of said building.

Defaults by Lessor

20.  In the event of a default by the Lessor under the Lease Agreement or an
     occurrence that would give rise to an offset against rent or claim against
     the Lessor under the Lease agreement, Tenant shall give any lender and the
     Lessor written notice of such default or occurrence at the respective
     addresses of such Lender and the Lessor and, if the Lessor has not cured or
     has not commenced and is diligently taking action to cure any such default,
     such lender may, at its option, cure such default or rectify such
     occurrence within thirty (30) days after receipt of such notice, or such
     additional period as may be necessary to cure for such default, provided
     that such lender uses reasonable diligence to correct the same. Tenant
     agrees that, notwithstanding any provision of the Lease Agreement to the
     contrary, it will not be entitled to cancel the Lease Agreement, or to
     abate or offset against the rent, or to exercise any other right or remedy
     until such lender and the Lessor have been given notice of default and
     opportunity to cure such default as provided herein.

Assignment of
Leases and Rents

21.  Tenant acknowledges that the Lessor has assigned the Lease Agreement and
     all rents and other payments due under the Lease Agreement to Eastern
     Heights State Bank of Saint Paul ("Leader") as security for a loan. Tenant
     further acknowledges that Lender may, at it's option, at any time after the
     occurrence of an event of default under that certain Construction Loan
     Agreement by and between the Lessor and Tender of any other "Loan
     Documents" described therein, direct that Tenant make all such rent and
     other payments directly to Lender or to any receiver duly appointed with
     respect to the Leased Premises by written notice to Tenant. Upon receipt of
     such notice, the Lessor hereby authorizes and directs Tenant and Tenant
     agrees to pay all such rent and other payments to Lender or to such
     receiver, as provided in said notice. The Lessor acknowledges that Tenant
     shall not be in default under the Lease if Tenant pays the rent and other
     payments to Lender pursuant to such notice. However, neither the giving of
     such notice by Lender nor the payment of rent and other payments due under
     the Lease to Lender shall affect the obligations of the Lessor under the
     Lease Agreement nor impose any obligations of the Lessor under the Lease
     Agreement upon Lender. Tenant agrees to provide Lender with a copy of its
     year end Balance sheet and Profit and Loss Statement within ninety (90)
     days of its year end. Tenant shall send the financial statements to Eastern
     Heights Bank, 670 McKnight Road North, St. Paul, MN 55119, attention: Brad
     Benesh

Consent of
Lender

22.  In the absence of the prior written consent of Lender, Tenant agrees not to
     do any of the following: (a) prepay the rent under the Lease Agreement for
     more than one (1) month in advance, (b) enter into any agreement with the
     Lessor to amend or modify the Lease in any material manner, or (c)
     sublease or assign the Leased Premises; provided, however, that no written
     consent of Lender is necessary if the sublease or assignment restricts the
     use of the Leased Premises to a real estate brokerage office, or general
     office use.

Tenant to Surrender
Premises in Good
Condition

23.  Upon the expiration or termination of the Lease Term, Tenant shall, at its
     expense, (I) remove Tenant's goods and effects and those of all persons
     claiming under Tenant, (ii) quit and deliver up the Leased Premises to
     Lessor, peaceably and quietly, in as good order and condition as the same
     were in on the date the Lease Term commenced or were thereafter placed in
     by Lessor, reasonable wear and tear excepted, and (iii) at Lessor's
     request, restore the Leased Premises to general office standards adopted
     from time to time by Lessor for general application throughout the
     Building(s). Any property left in the Leased Premises after the expiration
     or termination of the Lease Term shall be deemed to have been abandoned and
     the property of Lessor to be disposed of as Lessor deems expedient.

Waiver of
Covenants

24.  Failure of Lessor to insist, in any one or more instances, upon strict
     performance of any term, covenant or condition of this Lease, or to
     exercise any option herein contained, shall not be construed as a waiver or
     a relinquishment for the future of such term, covenant, condition or
     option, but the same shall continue and remain in full force and effect.
     The receipt by Lessor of rents with knowledge of a breach in any of the
     terms, covenants or conditions of this Lease to be kept or performed by
     Tenant shall not be deemed a waiver of such breach, and Lessor shall not be
     deemed to have waived any provision of this Lease unless expressed in
     writing and signed by Lessor.

Lessor's Rights to
Cure Defaults

25.  If Tenant defaults in the observance or performance of any of Tenant's
     covenants, agreements or obligations hereunder wherein the default can be
     cured by the expenditure of money, Lessor may, but without obligation, and
     without limiting any other remedies which it may have by reason of such
     default, cure the default, charge the cost thereof to Tenant and Tenant
     shall pay the same forthwith upon demand, together with interest thereon at
     the rate of eleven percent (11%) per annum.

Utilities

26.  Tenant shall pay to the appropriate utility company or companies when due
     all charges for utility services, including gas, electric and phone, except
     sewer and water which the Lessor is required to provide the Tenant, as
     provided for hereinabove.

Hazardous
Materials

     29. For the purposes of this Lease, "Hazardous Materials" shall mean (i)
     any "hazardous waste" as defined by the Resource Conservation and Recovery
     Act of 1976 (42 U.S.C. Section 6901 et seq.), as amended from time to time,
     and regulations promulgated thereunder, and (ii) any "hazardous substance"
     as defined by the Comprehensive Environmental Response, Compensation and
     Liability Act of 1980 (42 U.S.C. Section 9601 et seq.), as amended from
     time to time, and regulations promulgated thereunder.

     Lessor recognizes and agrees to Tenant's storage and use of substances
     including biological material required for the use of the Premises as
     permitted by this Lease. These substances may or may not fall into the
     category of defined by this Lease. Tenant agrees to limit the storage and
     use of those substances to the amounts required incidental to the normal
     business operations of Tenant permitted by this Lease at the Premises.

     Tenant agrees to defend, indemnify and hold harmless Lessor, its officers,
     employees, successors and assigns against any and all liability, damages,
     claims, demand actions or causes of action, including without limitation,
     penalties, and all costs, including attorney's fees, arising from or
     related to Tenant's handling, storage or use of Hazardous Material.
     Notwithstanding the foregoing, Tenant's indemnification of Lessor shall
     apply only if the Hazardous Material in question is determined to have been
     introduced by Tenant onto the Premises during Tenant's occupancy under this
     Lease. Tenant shall not be responsible for any violation of this Article 29
     by conditions existing prior to Tenant's occupancy of the premises. This
     indemnity shall survive the termination of this Lease.

     Lessor warrants, after due inquiry and investigation, that it has complied
     with, and has not received any notice of intent to commence any action or
     proceeding against the Lessor based on any violation of any building,
     zoning, land-use or environmental law, regulation or ordinance of any
     applicable jurisdiction in any respect which might adversely affect the
     Premises leased to Tenant under this Lease. Furthermore, Lessor warrants
     that Lessor's real property and the Premises leased to Tenant under this
     Lease have not been uses for the treatment, disposal or storage of
     Hazardous Materials (as defined above) which would subject Tenant to any
     damages, penalties or liabilities under any applicable federal, state or
     local law.

     In the event asbestos or other Hazardous Materials are found to have been
     present on the premises from prior to Tenant's occupancy, and the continued
     presence of same during the Lease terms interferes with Tenant's use and
     occupancy of the Premises during the Lease term, then Tenant shall, at its
     option, be permitted to terminate this Lease without further liability
     hereunder, or to require Lessor to remove the asbestos or other Hazardous
     Material.

MUTUAL COVENANTS 
OF LESSOR
AND TENANT       THE LESSOR AND TENANT MUTUALLY AGREE AS FOLLOWS:

Repairs

1.   The Tenant shall promptly pay to the Lessor, upon request, an amount equal
     to any cost incurred by the Lessor in repairing the Leased Premises and
     public areas in the Building(s) where such repairs were made necessary by
     the negligence of, or misuse by, the Tenant, its agents, employees or
     invitees.

Eminent Domain

2.   If the entire Building(s) is taken by eminent domain, this Lease shall
     automatically terminate as of the date of taking. If a portion of the
     Building(s)is taken by eminent domain, Lessor shall have the right to
     terminate this Lease by giving written notice thereof to Tenant within
     ninety (90) days after the date of taking. If a portion of the Leased
     Premises is taken by eminent domain and this Lease is not thereby
     terminated, Lessor shall, at its expense, restore the Leased Premises,
     exclusive of any improvements or other changes made to the premises by
     Tenant, to as near the condition which existed immediately prior to the
     date of taking as reasonably possible, and rent shall abate during such
     period of time as the leased Premises are untenantable, in the proportion
     that the untenantable portion of the Leased Premises bears to the entire
     Leased Premises.

Fire or Other
Casualty

3.   If the Building(s) is damaged or destroyed by fire or other casualty, the
     Lessor shall have the right to terminate this Lease provided it gives
     written notice thereof to the Tenant within ninety (90) days after such
     damage or destruction. If a portion of the Leased Premises is damaged by
     fire or other casualty, and this Lease is not thereby terminated, the
     Lessor shall, at its expense, restore the Leased Premises, exclusive of any
     improvements or other changes made to the premises by the Tenant, to as
     near the condition which existed immediately prior to such damage or
     destruction as reasonably possible, and rent shall abate during such period
     of time as the Leased Premises are untenantable, in the proportion that the
     untenantable portion of the Leased Premises bears to the entire Leased
     Premises. Tenant agrees that Lessor and its building manager and their
     officers, employees and agents shall not be liable to Tenant for any damage
     to or loss of personal property in the demised premises unless such damage
     or loss is the result of the negligence of Lessor, its building manager and
     their officers, employees or agents. Tenant agrees that it will insure
     itself for loss due to fire loss. The Lessor shall maintain fire insurance
     with extended coverage in amounts not less than those which are from time
     to time acceptable to a prudent owner in the area in which the Leased
     Premises are located. Such policies of insurance shall waive, to the extent
     available from the Lessor's insurance carrier, any right of subrogation
     against the Tenant.

Holding Over

4.   Should Tenant continue to occupy the Leased Premises or any part thereof
     after the expiration or termination of the Lease Term, such tenancy shall
     be from month to month. Tenant shall pay to Lessor the yearly rent, at
     double the rate payable for the year immediately preceding said holding
     over, computed on a per month basis for each month or part thereof the
     Tenant remains in possession. In addition thereto, Tenant shall pay to
     Lessor all damages, consequential as well as direct, sustained by reason of
     Tenant's retention of possession, Tenant shall continue to be subject to
     all other conditions and obligations of this Lease during said holding
     over. The provisions of this paragraph do not exclude Lessor's right of
     re-entry or any other right hereunder.

Defaults

5.   If Tenant shall default in the payment of any installment of rent, or in
     the observance or performance of any of Tenant's other covenants,
     agreements or obligations hereunder, or if any proceeding is commenced by
     or against Tenant for the purpose of subjecting the assets of Tenant to any
     law relating to bankruptcy or insolvency or for an appointment of a
     receiver of Tenant or of any Tenant's assets, or if Tenant makes a general
     assignment of Tenant's assets for the benefit of creditors, then in any
     such event, Lessor may, without process, re-enter immediately into the
     Leased Premises and remove all persons and property therefrom, and at its
     option, annul and cancel this lease as to all future rights of Tenant and
     have, regain, repossess and enjoy the Leased Premises, anything herein to
     the contrary notwithstanding, and Tenant hereby expressly waives the
     service of any notice in writing of intention to re-enter as aforesaid, and
     also all right of restoration to possession of the Leased Premises after
     re-entry or after judgment for possession thereof. In case of any such
     termination, Tenant will indemnify Lessor against all loss of rents and
     other damages which it may incur by reason of such termination during the
     residue of the lease Terms, and also against all attorney's fees and
     expenses incurred in enforcing any of the terms of this Lease.

Bill, Statement
and Notice

6.   A bill, statement, notice or communication which Lessor desires or is
     required to give to Tenant, including any notice of termination, shall be
     deemed sufficiently given or rendered if in writing, delivered to Tenant
     personally, or sent by registered or certified mail, addressed to Tenant at
     the Leased Premises, or left at the leased Premises, addressed to Tenant,
     and the time of rendition or giving shall be deemed to be the time when the
     same is delivered to Tenant, or mailed or left at the leased Premises as
     herein provided. Any notice by Tenant to Lessor must be served by
     registered or certified mail addressed to Lessor at the address where the
     last previous rental hereunder was payable, or upon notice given to Tenant,
     at such other place as Lessor designates.

Tenants

7.   The word "Tenant," wherever used in this lease, shall be construed to mean
     Tenants in all cases where there is more than one Tenant, and the necessary
     grammatical changes required to make the provisions hereof apply to
     corporations, partnerships or individuals, men or women, shall in all cases
     be assumed as though in each case fully expressed, each provision hereof
     shall extend to and shall, as the case may require, bind and inure to the
     benefit of Lessor and Tenant and their respective heirs, legal
     representatives, successors and assigns, provided that this Lease shall not
     inure to the benefit of any assignee, heir, legal representative,
     transferee or successor of Tenant except upon the express written consent
     or election of Lessor.

Relocation of
Leased Premises

8.   Lessor reserves the right to relocate the Tenant in substitute leased
     premises of equivalent square footage and configuration within the
     Building(s) upon one hundred twenty (120) days' written notice to the
     Tenant. If this right is exercised, Lessor shall, at its own expense,
     provide Tenant with paint, wall covering and carpeting and other finishes
     and improvements equivalent to existing leased space at the new location,
     comparable to those in the original location, and shall, at Lessor's own
     expense, move Tenant's office furnishings to the new location. Lessor shall
     reimburse tenant for expenses incurred by Tenant in relocating its
     telephone service. If the current rental rate at the new location is less
     than at the original location, the Tenant's rent shall be reduced
     accordingly. However, if the current rental rate at the new location is
     higher than at the original location, the Tenant's rent shall not be
     increased for the remainder of the term hereof. Tenant has the option of
     canceling this Lease by written notice within thirty (30) days of receiving
     notice of relocation.

Miscellaneous

9.   There are no understandings or agreements not incorporated in this Lease.
     This is a Minnesota Contract and shall be construed according to the laws
     of Minnesota. The captions in this Lease are for convenience only and are
     not a part of this Lease. The covenants and agreements hereof shall as
     fully and completely bind the heirs, executors, administrators, legal
     representatives, successors and assigns of the parties hereto as if they
     had been specifically mentioned in each of said covenants and agreements.

Tenant
Improvements

10.  See Exhibit "A" hereto attached and made a part of. Lessor will pay cost
     for interior finishes as identified in Exhibit "A" up to an allowance of
     $XXX,XXX.XX. Any additional cost for interior finishes as identified in
     Exhibit "A" shall be paid by Tenant.

Rules and
Regulations

11.  See Exhibit "B" hereto attached and made a part of.

Tenant Space

12.  See Exhibit "C" hereto attached and made a part of.

Amendment
of Lease

13.  See Exhibit "D" hereto attached and made a part of.


IN WITNESS WHEREOF, the respective parties hereto have executed this lease or
caused this lease to be executed by their duly authorized representative in
triplicate the day and year first above written.

OAKDALE PROPERTIES, LLC                    CELOX LABORATORIES, INC.
        LESSOR                                     TENANT

By:  ILLEGIBLE                             By: ILLEGIBLE
   ---------------------------------          ---------------------------------
Its: PARTNER                               Its:CHAIRMAN & CEO
   ---------------------------------          ---------------------------------



<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          AUG-31-1997
<PERIOD-END>                               FEB-28-1997
<CASH>                                         625,281
<SECURITIES>                                   737,213
<RECEIVABLES>                                   42,034
<ALLOWANCES>                                         0
<INVENTORY>                                     48,430
<CURRENT-ASSETS>                             1,464,959
<PP&E>                                         283,646
<DEPRECIATION>                                 207,882
<TOTAL-ASSETS>                               1,563,646
<CURRENT-LIABILITIES>                           62,663
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        27,422
<OTHER-SE>                                   1,473,561
<TOTAL-LIABILITY-AND-EQUITY>                 1,563,646
<SALES>                                        125,737
<TOTAL-REVENUES>                               125,737
<CGS>                                           61,894
<TOTAL-COSTS>                                  137,023
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (183,297)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (183,297)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (183,297)
<EPS-PRIMARY>                                    (0.07)
<EPS-DILUTED>                                    (0.07)
        


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission